Rubius Therapeutics Company
Rubius has developed the technology to grow, genetically engineer and mature long-circulating Red-Cell Therapeutics.
Last Funding Type:
Post-IPO Equity
Last Funding Date:
2021-03-17
Funding Status:
IPO
Headquarters:
Cambridge, Massachusetts, United States
Industry:
Atrificial Vectors and Immune Cells
Estimated Revenue:
$10M to $50M
Total Funding:
445000000
Investors Number:
1
Employee Number:
101-250
Founded Date:
2013-01-01